New Animal Drugs; Change of Sponsor's Name and Address, 40612 [2011-17292]
Download as PDF
<![CDATA[
40612
Federal Register / Vol. 76, No. 132 / Monday, July 11, 2011 / Rules and Regulations
§ 240.12a–11 Exemption of security-based
swaps sold in reliance on Securities Act of
1933 Rule 240 (§ 230.240) from section 12(a)
of the Act.
(a) The provisions of Section 12(a) of
the Act (15 U.S.C. 78l(a)) do not apply
to any security-based swap offered and
sold in reliance on Rule 240 under the
Securities Act of 1933.
(b) This rule will expire on the
compliance date for final rules that the
Commission may adopt further defining
both the terms security-based swap and
eligible contract participant. In such
event, the Commission will publish a
rule removing this section from 17 CFR
part 240 or modifying it as appropriate.
■ 5. Section 240.12h–1 is amended by
adding paragraph (i) to read as follows:
§ 240.12h–1 Exemptions from registration
under section 12(g) of the Act.
*
*
*
*
*
(i) Any security-based swap offered
and sold in reliance on Rule 240 under
the Securities Act of 1933. This rule will
expire on the compliance date for final
rules that the Commission may adopt
further defining both the terms securitybased swap and eligible contract
participant. In such event, the
Commission will publish a rule
removing this paragraph (i) from 17 CFR
part 240 or modifying it as appropriate.
PART 260—GENERAL RULES AND
REGULATIONS, TRUST INDENTURE
ACT OF 1939
6. The authority citation for Part 260
continues to read as follows:
■
Authority: 15 U.S.C. 77eee, 77ggg, 77nnn,
77sss, 78ll(d), 80b–3, 80b–4, and 80b–11.
7. Section 260.4d–12 is added to read
as follows:
■
§ 260.4d–12 Exemption for security-based
swaps offered and sold in reliance on
Securities Act of 1933 Rule 240 (§ 230.240).
erowe on DSK5CLS3C1PROD with RULES
Any security-based swap offered and
sold in reliance on Rule 240 of this
chapter (17 CFR 230.240), whether or
not issued under an indenture, is
exempt from the Act. This rule will
expire on the compliance date for final
rules that the Commission may adopt
further defining both the terms securitybased swap and eligible contract
participant. In such event, the
Commission will publish a rule
removing this section from 17 CFR part
260 or modifying it as appropriate.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 510
§ 510.600 Names, addresses, and drug
labeler codes of sponsors of approved
applications.
[Docket No. FDA–2011–N–0003]
*
New Animal Drugs; Change of
Sponsor’s Name and Address
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect a
change of sponsor’s name from
Alpharma, LLC, to Alpharma, LLC, a
wholly owned subsidiary of Pfizer, Inc.
The sponsor’s mailing address will also
be changed.
DATES: This rule is effective July 11,
2011.
Steven D. Vaughn, Center for Veterinary
Medicine (HFV–100), Food and Drug
Administration, 7520 Standish Pl.,
Rockville, MD 20855, 240–276–8300, email: steven.vaughn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Alpharma,
LLC, 400 Crossing Blvd., Bridgewater,
NJ 08807 has informed FDA of a change
of name and mailing address to
Alpharma, LLC, a wholly owned
subsidiary of Pfizer, Inc., 235 East 42d
St., New York, NY 10017. Accordingly,
the Agency is amending the regulations
in 21 CFR 510.600(c) to reflect these
changes.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 510
Administrative practice and
procedure, Animal drugs, Labeling,
Reporting and recordkeeping
requirements.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 510 is amended as follows:
PART 510—NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 510 continues to read as follows:
[FR Doc. 2011–17039 Filed 7–8–11; 8:45 am]
■
15:08 Jul 08, 2011
Authority: 21 U.S.C. 321, 331, 351, 352,
353, 360b, 371, 379e.
Jkt 223001
*
*
Firm name and address
Drug labeler
code
*
*
*
Alpharma, LLC, a wholly
owned subsidiary of Pfizer,
Inc., 235 East 42d St.,
New York, NY 10017 ........
*
*
*
*
*
046573
*
*
(2) * * *
Drug labeler
code
Firm name and address
*
*
046573 ...........
*
*
*
Alpharma, LLC, a wholly
owned subsidiary of
Pfizer, Inc., 235 East 42d
St., New York, NY 10017
FOR FURTHER INFORMATION CONTACT:
■
VerDate Mar<15>2010
*
*
(c) * * *
(1) * * *
Final rule.
SUMMARY:
By the Commission.
Dated: July 1, 2011.
Elizabeth M. Murphy,
Secretary.
BILLING CODE 8011–01–P
‘‘Alpharma LLC’’; and in the table in
paragraph (c)(2), revise the entry for
‘‘046573’’ to read as follows:
2. In § 510.600, in the table in
paragraph (c)(1), revise the entry for
PO 00000
Frm 00020
Fmt 4700
Sfmt 4700
*
*
*
*
*
Dated: July 1, 2011.
Elizabeth Rettie,
Deputy Director, Office of New Animal Drug
Evaluation, Center for Veterinary Medicine.
[FR Doc. 2011–17292 Filed 7–8–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
24 CFR Part 3500
[Docket No. FR–5180–F–07]
RIN 2502–AH85
Real Estate Settlement Procedures Act
(RESPA): Technical Corrections and
Clarifying Amendments
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Final rule.
AGENCY:
This final rule makes
technical corrections and certain
clarifying amendments to HUD’s RESPA
regulations promulgated by a final rule
published on November 17, 2008. The
majority of the regulations promulgated
by the November 17, 2008, final rule
became applicable on January 1, 2010.
Now that the regulations have been in
SUMMARY:
E:\FR\FM\11JYR1.SGM
11JYR1
]]>Agencies
[Federal Register Volume 76, Number 132 (Monday, July 11, 2011)]
[Rules and Regulations]
[Page 40612]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-17292]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 510
[Docket No. FDA-2011-N-0003]
New Animal Drugs; Change of Sponsor's Name and Address
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect a change of sponsor's name from Alpharma,
LLC, to Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc. The
sponsor's mailing address will also be changed.
DATES: This rule is effective July 11, 2011.
FOR FURTHER INFORMATION CONTACT: Steven D. Vaughn, Center for
Veterinary Medicine (HFV-100), Food and Drug Administration, 7520
Standish Pl., Rockville, MD 20855, 240-276-8300, e-mail:
steven.vaughn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Alpharma, LLC, 400 Crossing Blvd.,
Bridgewater, NJ 08807 has informed FDA of a change of name and mailing
address to Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc.,
235 East 42d St., New York, NY 10017. Accordingly, the Agency is
amending the regulations in 21 CFR 510.600(c) to reflect these changes.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling,
Reporting and recordkeeping requirements.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is
amended as follows:
PART 510--NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 510 continues to read as
follows:
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
0
2. In Sec. 510.600, in the table in paragraph (c)(1), revise the entry
for ``Alpharma LLC''; and in the table in paragraph (c)(2), revise the
entry for ``046573'' to read as follows:
Sec. 510.600 Names, addresses, and drug labeler codes of sponsors of
approved applications.
* * * * *
(c) * * *
(1) * * *
------------------------------------------------------------------------
Drug labeler
Firm name and address code
------------------------------------------------------------------------
* * * * *
Alpharma, LLC, a wholly owned subsidiary of Pfizer, 046573
Inc., 235 East 42d St., New York, NY 10017.............
* * * * *
------------------------------------------------------------------------
(2) * * *
------------------------------------------------------------------------
Drug labeler code Firm name and address
------------------------------------------------------------------------
* * * * *
046573.................................... Alpharma, LLC, a wholly
owned subsidiary of Pfizer,
Inc., 235 East 42d St., New
York, NY 10017
* * * * *
------------------------------------------------------------------------
Dated: July 1, 2011.
Elizabeth Rettie,
Deputy Director, Office of New Animal Drug Evaluation, Center for
Veterinary Medicine.
[FR Doc. 2011-17292 Filed 7-8-11; 8:45 am]
BILLING CODE 4160-01-P
